Zai Lab nabs speedy China regulatory review for PARP drug Zejula
Chinese regulatory officials are signaling that they’re ready to whisk Zejula through the regulatory process.
Zai Lab $ZLAB said this morning that the Center for Drug Evaluation of China’s National Medical Products Administration has offered a priority review for this drug, the PARP therapy niraparib in-licensed from Tesaro. They’re looking for an OK in China to market the drug for ovarian cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.